On June 9, the first batch of Xanomeline-Trospium (KarXT), Zai Lab’s new drug for the treatment of schizophrenia, left the company’s warehouse in SIP for market, offering a new therapeutic option for adult patients with schizophrenia.

KarXT is an oral M1/M4-preferring muscarinic acetylcholine receptor agonist for the treatment of psychiatric and neurological conditions. It has demonstrated statistically significant reductions of schizophrenia symptoms, while offering a superior safety profile that avoids common adverse reactions associated with traditional antipsychotic medications.

Zai Lab focuses on oncology, autoimmune diseases, infectious diseases, and central nervous system disorders, and is committed to providing innovative treatment solutions for global patients. It has over 20 product candidates in its pipeline, and 10 innovative products approved for marketing in China, demonstrating strong development resilience and innovation capabilities.

June 9, 2026